Hypertension and sex differences in the age-related renal changes when cyclooxygenase-2 activity is reduced during

Fara Sáez1, Virginia Reverte, Francisco Salazar

  • 1Department of Physiology, Aging Institute, University of Murcia, Murcia, Spain.

Insights

Decreased cyclooxygenase-2 (COX2) activity reduces nephron number and raises blood pressure similarly in male and female rats. However, males show greater age-dependent kidney damage and function decline.

Area of Science:

  • Nephrology
  • Developmental Biology
  • Cardiovascular Physiology

Background:

  • Cyclooxygenase-2 (COX2) is implicated in nephrogenesis.
  • Impaired nephrogenesis may contribute to hypertension development.

Purpose of the Study:

  • To investigate if reduced COX2 activity impacts nephron number, arterial pressure, and age-dependent renal alterations differently in male versus female rats.
  • To test the hypothesis linking decreased COX2 activity to hypertension and reduced nephron count.

Main Methods:

  • Rats were treated with a COX2 inhibitor or vehicle during nephrogenesis.
  • Arterial pressure was monitored from 1 to 16 months.
  • Stereological, histological, and renal function evaluations were performed.

Main Results:

  • COX2 inhibition reduced nephron number and increased arterial pressure similarly in both sexes.
  • Glomerular filtration rate and renal plasma flow declined significantly in males but not females.
  • Males exhibited greater age-dependent glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial damage.

Conclusions:

  • Reduced COX2 activity during development lowers nephron number and elevates arterial pressure equally in male and female rats.
  • Age-dependent renal structural and functional deterioration is significantly exacerbated in male rats following COX2 inhibition.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...